Kura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst Upgrade

Kura Oncology, Inc. (NASDAQ:KURA) saw unusually-strong trading volume on Friday after HC Wainwright raised their price target on the stock from $32.00 to $37.00. HC Wainwright currently has a buy rating on the stock. Approximately 1,545,867 shares traded hands during mid-day trading, an increase of 59% from the previous session’s volume of 970,186 shares.The stock last traded at $10.83 and had previously closed at $10.06.

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the company from $26.00 to $19.00 in a report on Monday, October 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. Finally, UBS Group started coverage on Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $29.38.

Institutional Trading of Kura Oncology

A number of institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC bought a new position in Kura Oncology during the third quarter valued at $25,000. SG Americas Securities LLC purchased a new position in shares of Kura Oncology during the first quarter valued at approximately $110,000. Point72 DIFC Ltd bought a new position in shares of Kura Oncology during the third quarter valued at approximately $146,000. Quarry LP purchased a new stake in shares of Kura Oncology in the second quarter worth approximately $196,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Kura Oncology during the 3rd quarter worth approximately $215,000.

Kura Oncology Trading Up 7.4 %

The stock has a fifty day moving average of $17.88 and a 200-day moving average of $19.69. The company has a market cap of $839.81 million, a PE ratio of -4.58 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.